Home › Sudden Cardiac Arrest › NCT05574296
Hydrogen's Feasibility and Safety as a Therapy in ECPR
Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation
Who can join
All ages · All sexes
Full eligibility criteria
INCLUSION CRITERIA In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Patients admitted to a cardiac intensive care unit at a participating site with cardiac comorbidity, including congenital heart disease, myocarditis, cardiac arrhythmia, or rejection of a transplanted heart. 2. Patients are anticipated to be between birth to 18 years of age, although occasionally a patient over the age of 18 may be enrolled. 3. Patient experiencing a refractory cardiac arrest \>5 minutes and receiving ongoing CPR in the ICU, cardiac catheterization lab, or cardiac operating room. 4. The decision made by the clinical team to resuscitate from ongoing, refractory cardiac arrest using ECPR due to a lack of other available options. EXCLUSION CRITERIA Meeting any of the following criterion renders the patient ineligible for the trial: 1. Enrollment in the opt-out program. 2. Patients known to be pregnant. 3. Patients who are prisoners. 4. Prior ECPR episode during admission (whether or not they were enrolled in the trial). 5. Enrollment does not occur within 6 hours of the decision to resuscitate using ECPR. Note that ECMO cannulation without preceding CPR does not qualify as ECPR and such patients will not be included.
About the study
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.
What is being tested
- Hydrogen (drug)
- Usual care (other)
Sponsor: Boston Children's Hospital · Participants: 53 · Started: Mar 4, 2024
Contact the study team
- John N Kheir, MD · Phone: 8576368890
Official record on ClinicalTrials.gov — NCT05574296
Locations in the U.S.
| District of Columbia | Children's National Hospital, Washington D.C. (Not yet recruiting) |
| Massachusetts | Boston Children's Hospital, Boston |
| Missouri | Children's Mercy Kansas City, Kansas City (Not yet recruiting) |
| Utah | Primary Children's Hospital, Salt Lake City (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.